Historical Stock Chart
6 Months : From May 2019 to Nov 2019
By Colin Kellaher
Synlogic Inc. (SYBX) on Wednesday said it plans to study its SYNB1891 Synthetic Biotic medicine in combination with Roche Holding AG's (ROG.EB) cancer immunotherapy Tecentriq in patients with advanced solid tumors under a collaboration with the Swiss drugmaker.
Synlogic, a Cambridge, Mass., clinical-stage biopharmaceutical company, said it expects to file an investigational new drug application with the U.S. Federal Drug Administration to begin an open-label Phase 1 clinical trial evaluating SYNB1891 as a monotherapy and a combination treatment with Tecentriq.
Synlogic said it will sponsor the study, while Roche will provide the clinical supply of Tecentriq.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
May 22, 2019 08:04 ET (12:04 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.